Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells.
Azintuxizumab vedotin (ABBV-838) is an ADC comprising a humanized recombinant immunoglobulin G1κ directed against a unique epitope of CD2 subset 1 (CS1, also known as SLAMF7) conjugated to the cytotoxic monometl auristatin E (MMAE) through a valine-citrulline linker[1].Azintuxizumab vedotin shows potent cytotoxic activity against cancer cells that expressed CS1[1].
Azintuxizumab vedotin (ABBV-838) shows single-agent antitumor activity in mouse models using human myeloma xenografts[1].
References:
[1]. Vij R, et al. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 May 15;26(10):2308-2317.